CSCMY yields 0.71% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, CSCMY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CSCMY + PFE for your $10,000?
COSCO SHIPPING International (Singapore) Co., Ltd., an investment holding company, provides integrated logistics services in South and Southeast Asia. It operates through Shipping, Ship Repair and Marine Engineering Activities, Logistics, and Property Management segments. The company's logistics services include warehousing management, ISO tank and container depot management, automotive logistics, and transport management to SMEs and multinational companies. It also offers forwarding and shipping; property investment, trading, and management services; and dry bulk cargo transportation services comprising grains, iron ore, coal, steel, cement, and fertilizers through 3 vessels, as well as ship repair and marine engineering services. In addition, the company provides export processing, transportation, and storage of motor vehicles, as well as hostel management services; and engages in ship owning and chartering activities. Further, it offers container repair, fabrication work, freight management, and warehouse rental services; and produces marine outfitting components. The company was formerly known as COSCO Corporation (Singapore) Limited and changed its name to COSCO SHIPPING International (Singapore) Co., Ltd. in April 2017. The company was incorporated in 1961 and is based in Singapore. COSCO SHIPPING International (Singapore) Co., Ltd. is a subsidiary of China Ocean Shipping Company Limited.
Full CSCMY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.